244 related articles for article (PubMed ID: 33147420)
1. Behçet's disease uveitis: is there a need for new emerging drugs?
Tugal-Tutkun I; Çakar Özdal P
Expert Opin Emerg Drugs; 2020 Dec; 25(4):531-547. PubMed ID: 33147420
[No Abstract] [Full Text] [Related]
2. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.
Fabiani C; Vitale A; Emmi G; Lopalco G; Vannozzi L; Guerriero S; Gentileschi S; Bacherini D; Franceschini R; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
Clin Rheumatol; 2017 Jan; 36(1):191-197. PubMed ID: 27981463
[TBL] [Abstract][Full Text] [Related]
3. [Uveitic glaucoma in Behçet's disease: When everything gets complicated].
Belkhadir K; Boutimzine N; Tachfouti S; Laghmari M; Amazouzi A; Cherkaoui O
J Fr Ophtalmol; 2020 Sep; 43(7):635-641. PubMed ID: 32622636
[TBL] [Abstract][Full Text] [Related]
4. Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis.
Fabiani C; Sota J; Vitale A; Emmi G; Vannozzi L; Bacherini D; Lopalco G; Guerriero S; Venerito V; Orlando I; Franceschini R; Fusco F; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
Ocul Immunol Inflamm; 2019; 27(1):34-39. PubMed ID: 29099660
[TBL] [Abstract][Full Text] [Related]
5. [Ocular manifestations in Behçet's disease].
Desbois AC; Terrada C; Cacoub P; Bodaghi B; Saadoun D
Rev Med Interne; 2018 Sep; 39(9):738-745. PubMed ID: 29625716
[TBL] [Abstract][Full Text] [Related]
6. Current and future treatments for Behçet's uveitis: road to remission.
Mesquida M; Molins B; Llorenç V; Hernández MV; Espinosa G; Dick AD; Adán A
Int Ophthalmol; 2014 Apr; 34(2):365-81. PubMed ID: 23729309
[TBL] [Abstract][Full Text] [Related]
7. [Ocular manifestations in Behçet's disease].
Zeghidi H; Saadoun D; Bodaghi B
Rev Med Interne; 2014 Feb; 35(2):97-102. PubMed ID: 24290834
[TBL] [Abstract][Full Text] [Related]
8. Eye and Behçet's disease.
Ksiaa I; Abroug N; Kechida M; Zina S; Jelliti B; Khochtali S; Attia S; Khairallah M
J Fr Ophtalmol; 2019 Apr; 42(4):e133-e146. PubMed ID: 30850197
[TBL] [Abstract][Full Text] [Related]
9. Emerging drugs for the treatment of noninfectious uveitis.
Pleyer U; Pohlmann D; Kardeş E; Poddubnyy D; Rademacher J
Expert Opin Emerg Drugs; 2019 Sep; 24(3):173-190. PubMed ID: 31498689
[No Abstract] [Full Text] [Related]
10. An update on the use of biologic therapies in the management of uveitis in Behçet's disease: a comprehensive review.
McNally TW; Damato EM; Murray PI; Denniston AK; Barry RJ
Orphanet J Rare Dis; 2017 Jul; 12(1):130. PubMed ID: 28716038
[TBL] [Abstract][Full Text] [Related]
11. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet's disease: multicentre retrospective study.
Atienza-Mateo B; Calvo-Río V; Beltrán E; Martínez-Costa L; Valls-Pascual E; Hernández-Garfella M; Atanes A; Cordero-Coma M; Miquel Nolla J; Carrasco-Cubero C; Loricera J; González-Vela MC; Vegas-Revenga N; Fernández-Díaz C; Demetrio-Pablo R; Domínguez-Casas LC; Luis Martín-Varillas J; Palmou-Fontana N; Hernández JL; González-Gay MÁ; Blanco R
Rheumatology (Oxford); 2018 May; 57(5):856-864. PubMed ID: 29471416
[TBL] [Abstract][Full Text] [Related]
12. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.
Fabiani C; Vitale A; Emmi G; Vannozzi L; Lopalco G; Guerriero S; Orlando I; Franceschini R; Bacherini D; Cimino L; Soriano A; Frediani B; Galeazzi M; Iannone F; Tosi GM; Salvarani C; Cantarini L
Clin Rheumatol; 2017 Jan; 36(1):183-189. PubMed ID: 27853889
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A
Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic factors of ocular involvement in Behçet's disease].
Belkhadir K; Boutimzine N; Laghmari M; Amazouzi A; Tachfouti S; Cherkaoui O
J Fr Ophtalmol; 2019 Jun; 42(6):612-617. PubMed ID: 31088739
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of TNF-alpha antagonist and other immunomodulators in the treatment of patients with ophthalmologic manifestations of Behcet's disease and HLA B51 positive vasculitis].
Zlatanović G; Jovanović S; Veselinović D; Zivković M
Vojnosanit Pregl; 2012 Feb; 69(2):168-74. PubMed ID: 22500372
[TBL] [Abstract][Full Text] [Related]
17. [Eye and Behçet's disease].
Ksiaa I; Abroug N; Kechida M; Zina S; Jelliti B; Khochtali S; Attia S; Khairallah M
J Fr Ophtalmol; 2019 Jun; 42(6):626-641. PubMed ID: 31164292
[TBL] [Abstract][Full Text] [Related]
18. Treatment of ocular manifestations of Behçet's disease.
Davatchi F
Adv Exp Med Biol; 2003; 528():487-91. PubMed ID: 12918750
[No Abstract] [Full Text] [Related]
19. Risk factors, clinical features and treatment of Behçet's disease uveitis.
Zhong Z; Su G; Yang P
Prog Retin Eye Res; 2023 Nov; 97():101216. PubMed ID: 37734442
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of biological therapy compared to synthetic immunomodulatory drugs or placebo in the treatment of Behçet's disease associated uveitis: a systematic review.
Urruticoechea-Arana A; Cobo-Ibáñez T; Villaverde-García V; Santos Gómez M; Loza E; Vargas-Osorio K; Fariñas Padrón L; Diaz-Gonzalez F; Calvo-Río V; Blanco R
Rheumatol Int; 2019 Jan; 39(1):47-58. PubMed ID: 30421105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
